What a Blood Marker May Reveal About MS Disability

Credibility

Interest

Share:2 min read

Key Takeaway

People with MS were more likely than people without MS to have a blood marker that looked older than their actual age, especially if they had greater disability or progressive MS.

What They Found

Researchers compared blood samples from 792 people with MS and 302 people without MS. They measured neurofilament light chain, or NfL, a substance released when nerve fibers are damaged. They used each person’s NfL level to estimate a marker-based age, then compared it with their actual age. People with MS were more likely to have a marker-based age above their actual age, even though they had no recent signs of new MS activity. A larger age gap was linked to greater disability, progressive MS, and having tried more MS treatments in the past.

Who Should Care and Why

These findings may matter to people with MS whose symptoms worsen even when scans show no new activity. The NfL age gap could give care teams another clue about nerve health, like an extra gauge on a car dashboard. It does not replace conversations about symptoms, disability checks, or MRI scans. If you are concerned about changes in walking or other daily activities, tell your MS care team, even if a recent scan was stable. Caregivers can help by noting changes over time and bringing those observations to appointments.

Important Considerations

This study looked back at existing records, so it cannot show that an older marker-based age causes disability. It included people with no recent signs of new MS activity, so the findings may not apply in the same way during a relapse. An NfL-based age is a comparison tool, not a measure of how old someone’s body truly is or a reason to change treatment on its own.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Genetics Clinical Trials Mental Wellness

Article Topics:

Multiple sclerosisageingneurofilament light chain

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News